Last reviewed · How we verify
Melphalan chemosaturation via percutaneous hepatic perfusion
Melphalan chemosaturation via percutaneous hepatic perfusion is a Small molecule drug developed by Leiden University Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | Melphalan chemosaturation via percutaneous hepatic perfusion |
|---|---|
| Sponsor | Leiden University Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PHP and Immunotherapy in Metastasized UM (PHASE1, PHASE2)
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melphalan chemosaturation via percutaneous hepatic perfusion CI brief — competitive landscape report
- Melphalan chemosaturation via percutaneous hepatic perfusion updates RSS · CI watch RSS
- Leiden University Medical Center portfolio CI
Frequently asked questions about Melphalan chemosaturation via percutaneous hepatic perfusion
What is Melphalan chemosaturation via percutaneous hepatic perfusion?
Melphalan chemosaturation via percutaneous hepatic perfusion is a Small molecule drug developed by Leiden University Medical Center.
Who makes Melphalan chemosaturation via percutaneous hepatic perfusion?
Melphalan chemosaturation via percutaneous hepatic perfusion is developed by Leiden University Medical Center (see full Leiden University Medical Center pipeline at /company/leiden-university-medical-center).
What development phase is Melphalan chemosaturation via percutaneous hepatic perfusion in?
Melphalan chemosaturation via percutaneous hepatic perfusion is in Phase 1.
Related
- Manufacturer: Leiden University Medical Center — full pipeline